
Amgen (NASDAQ:AMGN) has spent five years replacing aging blockbusters with a newer growth portfolio, and 2026 is the year that shift showed up in the numbers. Management raised its full-year outlook in August and again in November, and the stock is up 44.13% year to date.
Out With Prolia, In With Repatha and IMDELLTRAAmgen’s legacy franchises are shrinking fast. In the third quarter, Prolia fell 45%, and XGEVA dropped 47% as biosimilars launched globally. Medicare Part D price setting under the Inflation Reduction Act also cut Enbrel’s net selling price by 14%. The Horizon Therapeutics acquisition, which closed in 2023, brought in rare-disease drugs like UPLIZNA and TEPEZZA, plus debt that remains at $54.0 billion.
The newer drugs are now making up the difference. Third-quarter revenue reached $10.365 billion, up 8.45%. Repatha brought in $1.085 billion (+37%), UPLIZNA grew 191%, and IMDELLTRA rose 128%. Non-GAAP EPS of $6.45 exceeded the $5.7822 consensus, the sixth consecutive beat.
February’s starting guidance called for revenue of $37.0 billion to $38.4 billion and non-GAAP EPS of $21.60 to $23.00. After six key growth drivers rose 26% in the second quarter, Amgen lifted that to $38.2 billion to $39.4 billion and $22.30 to $23.50. November’s raise moved it to $38.9 billion to $39.7 billion and $22.90 to $23.70.
Your $1,000 Became $2,603 and Beat the Market EverywhereAmgen returns include reinvested dividends, while the SPY benchmark reflects price changes only. Including SPY’s dividends would narrow Amgen’s reported lead. The S&P 500 benchmark uses the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) price change.
1-Year Return
5-Year Return
10-Year Return
Timing counted, as shares sat at $338.01 when first-quarter results landed in April, then reached $466.36 by the November report. Holders needed patience while biosimilars ate into Prolia before the newer drugs took over.
A 20x Earnings Multiple and a MariTide Catalyst Shape the OutlookInvestors are betting that Repatha, IMDELLTRA and UPLIZNA keep outpacing biosimilar erosion and that MariTide, a monthly obesity candidate in Phase 3, reaches market. At its November 13 closing price of $465.67, Amgen trades at roughly 20 times the midpoint of its 2026 adjusted EPS guidance. Management also stated, “we do not anticipate a step-down in operating margin” in 2027.
Skeptics worry that MariTide could stumble against established GLP-1 rivals, since the obesity program carries much of the long-term premium. The FDA’s request to withdraw TAVNEOS and the heavy debt load add pressure. On balance, a diversified portfolio is overcoming its decline at a reasonable multiple.